metformin has been researched along with Central Nervous System Diseases in 2 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Central Nervous System Diseases: Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the use of oral glucose tolerance testing (OGTT) to predict efficacy of insulin sensitization (metformin) or suppression (octreotide) because insulin resistance and insulin hypersecretion may impact pharmacotherapeutic efficacy in obese children." | 5.12 | Insulin dynamics predict body mass index and z-score response to insulin suppression or sensitization pharmacotherapy in obese children. ( Bacchetti, P; Christensen, ML; Lazar, AA; Lustig, RH; Mietus-Snyder, ML; Velasquez-Mieyer, PA, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tao, T | 1 |
| Yang, Y | 1 |
| Hu, Z | 1 |
| Lustig, RH | 1 |
| Mietus-Snyder, ML | 1 |
| Bacchetti, P | 1 |
| Lazar, AA | 1 |
| Velasquez-Mieyer, PA | 1 |
| Christensen, ML | 1 |
1 trial available for metformin and Central Nervous System Diseases
| Article | Year |
|---|---|
Insulin dynamics predict body mass index and z-score response to insulin suppression or sensitization pharmacotherapy in obese children.
Topics: Adolescent; Black People; Blood Glucose; Body Mass Index; Central Nervous System Diseases; Child; Ch | 2006 |
1 other study available for metformin and Central Nervous System Diseases
| Article | Year |
|---|---|
A novel HNF1B mutation p.R177Q in autosomal dominant tubulointerstitial kidney disease and maturity-onset diabetes of the young type 5: A pedigree-based case report.
Topics: Aftercare; Central Nervous System Diseases; Dental Enamel; Diabetes Mellitus, Type 2; Hepatocyte Nuc | 2020 |